This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yano, M. Articles by Matsuzaki, M. Search for Related Content PubMed PubMed Citation Articles by Yano, M. Articles by Matsuzaki, M. Related Collections Heart failure - basic studies

(Circulation. 2000;102:2131.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Altered Stoichiometry of FKBP12.6 Versus Ryanodine Receptor as a Cause of Abnormal Ca²⁺ Leak Through Ryanodine Receptor in Heart Failure

Masafumi Yano, MD, PhD; Kaoru Ono, MD; Tomoko Ohkusa, MD, PhD; Masae Suetsugu, BS; Masateru Kohno, MD; Takayuki Hisaoka, MD; Shigeki Kobayashi, MD, PhD; Yuji Hisamatsu, MD, PhD; Takeshi Yamamoto, MD, PhD; Michihiro Kohno, MD, PhD; Naoya Noguchi, MD, PhD; Shin Takasawa, MD, PhD; Hiroshi Okamoto, MD, PhD; Masunori Matsuzaki, MD, PhD

From the Second Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, and the Department of Biochemistry, Tohoku University Graduate School of Medicine, Sendai (N.N., S.T., H.O.), Japan.

Correspondence to Masafumi Yano, MD, PhD, Second Department of Internal Medicine, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan. E-mail yanoma{at}po.cc.yamaguchi-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—In the pathogenesis of cardiac dysfunction in heart failure, a decrease in the activity of the sarcoplasmic reticulum (SR) Ca²⁺-ATPase is believed to be a major determinant. Here, we report a novel mechanism of cardiac dysfunction revealed by assessing the functional interaction of FK506–binding protein (FKBP12.6) with the cardiac ryanodine receptor (RyR) in a canine model of pacing-induced heart failure.

Methods and Results—SR vesicles were isolated from left ventricular muscles (normal and heart failure). The stoichiometry of FKBP12.6 per RyR was significantly decreased in failing SR, as assessed by the ratio of the B_max values for [³H]dihydro-FK506 to those for [³H]ryanodine binding. In normal SR, the molar ratio was 3.6 (1 FKBP12.6 for each RyR monomer), whereas it was 1.6 in failing SR. In normal SR, FK506 caused a dose-dependent Ca²⁺ leak that showed a close parallelism with the conformational change in RyR. In failing SR, a prominent Ca²⁺ leak was observed even in the absence of FK506, and FK506 produced little or no further increase in Ca²⁺ leak and only a slight conformational change in RyR. The level of protein expression of FKBP12.6 was indeed found to be significantly decreased in failing SR.

Conclusions—An abnormal Ca²⁺ leak through the RyR is present in heart failure, and this leak is presumably caused by a partial loss of RyR-bound FKBP12.6 and the resultant conformational change in RyR. This abnormal Ca²⁺ leak might possibly cause Ca²⁺ overload and consequent diastolic dysfunction, as well as systolic dysfunction.

Key Words: sarcoplasmic reticulum • heart failure • calcium • ion channels

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
In cardiac muscle, a small amount of Ca²⁺ entering through the L-type Ca²⁺ channel induces the release of a large amount of Ca²⁺ from the sarcoplasmic reticulum (SR) through the Ca²⁺ release channel, also referred to as the ryanodine receptor (RyR).^{1 2 3 4}

An associated protein, FKBP12, has been found to be copurified with RyR during sucrose density gradient centrifugation.⁵ The physiological function of FKBP12 is modulation of RyR-1, the skeletal muscle isoform of the Ca²⁺ release channel, possibly by enhancing cooperation among its 4 subunits.^{5 6 7} Recently, a novel FKBP with a different electrophoretic mobility (FKBP12.6) was found to be specifically associated with RyR-2, the cardiac muscle isoform of the Ca²⁺ release channel.^{8 9} FKBP12.6 has 85% homology with FKBP12.¹⁰ The stoichiometry of binding is 4 mol FKBP per RyR tetramer (or 1 FKBP to 1 RyR monomer) in both skeletal muscle and cardiac muscle. However, in contrast to the effects of FKBP12 on RyR-1, there is controversy as to the modulatory influence exerted by FKBP12.6 over RyR-2. Kaftan et al¹¹ found that rapamycin, a drug that inhibits the prolyl isomerase activity of FKBP12.6 and dissociates FKBP12.6 from RyR-2, increases the open probability and reduces the current amplitude of cardiac Ca²⁺ release channels. Conversely, Timerman et al⁹ showed that removal of FKBP12.6 from the canine RyR-2 by FK590 (FK506 analogue) produced no appreciable effect on the sensitivity of the channel to the activating Ca²⁺.

Previously,¹² we demonstrated that in a pacing-induced canine heart failure model, the rate of polylysine-induced Ca²⁺ release from the SR vesicles was significantly decreased, suggesting that the gating function of the SR Ca²⁺ release channel in response to the release trigger polylysine is altered in heart failure. When we found that the addition of FK506 to normal SR vesicles decreased the rate of drug-induced Ca²⁺ release toward that seen in failing SR vesicles (unpublished data), we hypothesized that the mode of interaction between FKBP12.6 and the RyR-2 may be altered in heart failure and that this might be the major cause of the impaired channel gating function. The goal of this study was to investigate this hypothesis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Materials
Fluo 3 was obtained from Molecular Probes, and sulfosuccinimidyl 3-((2-(7-azido-4-methylcoumarin-3-acetamido)ethyl)dithio)propionate (SAED) was from Pierce. FK506 was provided by Fujisawa Pharmaceutical Co, Ltd. [³H]ryanodine and [³H]dihydro-FK506 were purchased from Dupont NEN. A monoclonal antibody against the canine cardiac ryanodine receptor was from Affinity Bioreagents, Inc. Rat recombinant FKBP12.6 and rabbit anti-FKBP12.6 antiserum directed against the sequence KKFDSSRDRNKPFK were used for immunoblot analysis.¹³

Production of Pacing-Induced Heart Failure
In 12 beagle dogs of either sex weighing 10 to 14 kg, heart failure was induced by 21 day of rapid ventricular pacing at a rate of 250 bpm with an externally programmable miniature pacemaker (Medtronic Inc), as described previously.¹² Approximately 1 hour after termination of rapid ventricular pacing, left ventricular (LV) pressure was measured under anesthesia by way of a 7F micromanometer (Millar) inserted percutaneously via the carotid artery, and 2D short-axis echocardiograms were obtained at the level of the head of the papillary muscle.

The care of the animals and the protocols used were in accord with guidelines laid down by the Animal Ethics Committee of Yamaguchi University School of Medicine.

Preparation of SR Vesicles
SR vesicles were prepared as described previously,^{12 14} according to the method of Kranias et al.¹⁵

[³H]Dihydro-FK506 and [³H]Ryanodine Binding Assays
[³H]Dihydro-FK506 binding was performed in CHAPS-solubilized SR by the LH-20 column method^{8 16 17} with some modifications. The SR vesicles (0.1 mg/mL) were first solubilized in FK506-binding buffer (20 mmol/L NaPO₄ [pH 7.2], 0.5% CHAPS, 2 mmol/L DTT, 5 mg/mL BSA, and 0.02% NaN₃). Then, the solubilized vesicles were incubated for 30 minutes at 37°C in a binding mixture containing 1.25 to 20 nmol/L [³H]dihydro-FK506 (55 000 cpm/pmol). After this incubation, the samples were applied to a 3-mL Sephadex LH-20 column equilibrated in LH-20 column buffer (10 mmol/L NaPO₄, 1 mmol/L DTT, 0.25% CHAPS, and 0.01% NaN₃) to separate free from bound ligand. Nonspecific binding was determined by the addition of 30 µmol/L unlabeled FK506.

The density of high-affinity [³H]ryanodine binding sites in SR vesicles was determined by Scatchard analysis of [³H]ryanodine binding isotherms, as described previously.^{12 14} The stoichiometry of FKBP per RyR was calculated directly from the ratio of the maximal number of binding sites (B_max) values for [³H]dihydro-FK506 binding and [³H]ryanodine binding.^{8 17}

Ca²⁺ Uptake and Leak Assays
SR vesicles (0.2 mg/mL) were incubated in 0.5 mL of solution containing 0.15 mol/L potassium gluconate, 1 mmol/L MgCl₂, 0.2 mmol/L EGTA-calcium buffer (free [Ca²⁺] 0.3 µmol/L), 10 mmol/L NaN₃, and 20 mmol/L MOPS, pH 6.8. Ca²⁺ uptake was initiated by the addition of 0.5 mmol/L ATP into the cuvette, and the time course of Ca²⁺ uptake was monitored spectrophotometrically with fluo 3 as a Ca²⁺ indicator (excitation at 480 nm, emission at 530 nm). After the Ca²⁺ uptake had reached a plateau, various concentrations of FK506 were added in the presence of 1 µmol/L thapsigargin to inhibit SR Ca²⁺-ATP activity, and the resultant Ca²⁺ leak was monitored.

Site-Directed Labeling of RyR With a Fluorescent Conformational Probe
Specific fluorescence labeling of the RyR in SR vesicles was performed with the cleavable heterobifunctional cross-linking reagent SAED with the aid of polylysine as a site-specific carrier, as described previously.^{18 19 20} The specific methyl-coumarin-acetamido (MCA) labeling of the RyR in cardiac SR vesicles was confirmed by a fluorometric scan (excitation at 360 nm, emission at 440 nm) with a fluorescence spectrophotometer (F-2000; Hitachi) after electrophoresis had been carried out on 4% SDS-polyacrylamide gel.

Fluorescence Assays of the Protein Conformational Change
The time course of the FK506-induced changes in the fluorescence intensity of the RyR-bound MCA probe (excitation at 360 nm, emission at 440 nm) was monitored under the same conditions as those used for the Ca²⁺ leak assay (except that there was no fluo 3 in the reaction solution) with a fluorescence spectrophotometer (F-2000; Hitachi).

Immunoblot Analysis
Immunoblot analysis for FKBP12.6 was performed as previously described.¹³ Cardiac SR vesicles were electrophoresed on 15% gel for FKBP12.6 with Laemmli’s buffer system. The amount of protein recognized by anti-FKBP12.6 antiserum was measured by quantitative densitometry of immunoblots with NIH Image (National Institutes of Health) image-analysis software. Recombinant FKBP12.6 was loaded in the range 10 to 50 ng. Within this range, a linear increase in the density of FKBP12.6 was obtained by quantitative densitometry. The relative activity associated with FKBP12.6 in each sample (100 µg) was calculated by dividing its activity by that of the positive control (20 ng of recombinant FKBP12.6).

Statistics
Differences between 2 groups were analyzed with an unpaired t test. Statistical significance was taken at a value of P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Characteristics of Animal Models
There were no significant differences between normal and heart failure groups in body weight (kg; normal 11±1, heart failure 11±3), LV weight (g; normal 56±7, heart failure 65±11), or protein yield with respect to SR vesicles (mg protein/g; normal 1.4±0.4, heart failure 1.2±0.2).

Hemodynamic data are summarized in Table 1. In the heart failure group, LV end-diastolic pressure was significantly elevated, and both the peak +dP/dt of LV pressure and the fractional shortening were decreased, whereas the time constant of the LV pressure decay during the isovolumic relaxation period () was increased. These data indicate that both systolic and diastolic functions were impaired in the heart failure group.

View this table: [in this window] [in a new window]   Table 1. Hemodynamic Data

[³H]Dihydro-FK506 and [³H]Ryanodine Binding to Normal and Failing SR Vesicles
As shown in Figure 1 and summarized in Table 2, the B_max values for both [³H]ryanodine binding and [³H]dihydro-FK506 binding in SR vesicles were significantly lower in the failing group than in the normal group. Because the RyR contains a single high-affinity ryanodine binding site per tetramer, the ratio of binding (B_max) for [³H]dihydro-FK506 to high-affinity [³H]ryanodine in SR vesicles provides an estimate of the molar ratio of FKBP per Ca²⁺ release channel.¹⁷ In normal SR vesicles, the molar ratio was 3.6, indicating that SR vesicles have 4 mol FKBP per tetramer (ie, 1 FKBP for each monomer of the Ca²⁺ release channel). In contrast, the molar ratio was 1.6 in the failing SR vesicles, indicating that 2 to 3 mol FKBP have been lost from each tetramer of the Ca²⁺ release channel.

View larger version (15K): [in this window] [in a new window]   Figure 1. [3H]dihydro-FK506 binding to SR vesicles isolated from normal () and failing (•) canine hearts. [3H]dihydro-FK506 binding to SR vesicles was measured as described under Methods. Data are representative of 6 different preparations. Each datum point is average of duplicate determinations. Inset: Scatchard replot of binding data.

View this table: [in this window] [in a new window]   Table 2. [4 H]Ryanodine and [4 H]Dihydro-FK506 Bindings to the SR Vesicles Isolated From Normal and Failing Hearts

Effects of FK506 on Ca²⁺ Leak and Conformational Change of RyR
Figure 2A shows the time course of the Ca²⁺ leak induced by FK506 (30 µmol/L) plus 1 µmol/L thapsigargin, after the Ca²⁺ uptake induced by MgATP. We confirmed that 1 µmol/L thapsigargin completely inhibited the Ca²⁺ uptake when it was added together with MgATP to the priming solution containing SR vesicles. In accord with our previous finding,¹² the Ca²⁺ uptake was decreased in failing SR vesicles by comparison with that in the normal SR vesicles. After the addition of FK506 (30 µmol/L) in the presence of 1 µmol/L thapsigargin, a Ca²⁺ leak was observed in normal SR vesicles. In contrast, in the failing SR vesicles, a prominent Ca²⁺ leak was observed even without FK506, and FK506 had no further effect on this spontaneous Ca²⁺ leak. Ruthenium red 10 µmol/L plus Mg²⁺ 10 mmol/L (which inhibits Ca²⁺ release and drug-induced Ca²⁺ release through the RyR)^{14 21} almost completely inhibited the FK506-induced Ca²⁺ leak in normal SR vesicles and also the spontaneous Ca²⁺ leak in failing SR vesicles. When FK506 was added before the addition of MgATP, the amount of Ca²⁺ uptake was reduced in normal SR vesicles, but it was unchanged in failing SR vesicles. In both groups, the amount of Ca²⁺ uptake (nmol · mg^-1 · min^-1; normal 13.6±2.9, failure 8.9±1.3) was not significantly influenced by 30 µmol/L FK506 (nmol · mg^-1 · min^-1; normal 14.2±2.0, failure 8.3±1.1) in the presence of 10 mmol/L Mg²⁺ and 10 µmol/L ruthenium red. These data indicate that the Ca²⁺ leak is solely ascribable to the problem with RyR and that FK506 does not have a direct effect on SR Ca²⁺ uptake.

View larger version (23K): [in this window] [in a new window]   Figure 2. A, Representative time courses of Ca2+ uptake and ensuing Ca2+ leak in SR vesicles isolated from normal and failing canine hearts. Change in extravesicular Ca2+ concentration was measured with fluo 3, as described under Methods. B, Effect of various concentrations of FK506 on SR Ca2+ leak in SR vesicles isolated from normal (, n=6) and failing (•, n=6) canine hearts. Data represent mean±SD.

Figure 2B shows the concentration-dependence of the FK506 (0 to 100 µmol/L)–induced Ca²⁺ leak in the 2 types of SR vesicles. After the addition of FK506, a Ca²⁺ leak was induced in a dose-dependent manner in normal SR vesicles. In failing SR vesicles, however, a prominent Ca²⁺ leak was observed even in the absence of FK506, and the addition of FK506 produced little or no further increase in Ca²⁺ leak.

Figure 3 shows the specific incorporation of MCA into the RyR moiety of the SR, as determined by fluorometry of the electrophoretically separated proteins. Fluorometric scanning (excitation at 360 nm, emission at 440 nm) revealed that MCA fluorescence was clearly localized in RyR in both normal and failing SR vesicles, no other bands being fluorescently labeled. Figure 4A shows typical examples of the changes in MCA fluorescence produced by the addition of FK506 under the same conditions as those used for the Ca²⁺ leak assay. After Ca²⁺ uptake, the addition of FK506 induced an increase in MCA fluorescence at a faster rate than that of the Ca²⁺ leak in normal SR vesicles (compare Figure 4A with Figure 2A), whereas it produced only a slight increase in MCA fluorescence in failing SR vesicles. As shown in Figure 4B, in normal SR vesicles, the amplitude of the FK506-induced change in MCA fluorescence increased as the concentration of FK506 was increased. In failing SR vesicles, however, FK506 produced only a small effect on MCA fluorescence even at its highest concentrations. FK506 had no effect on the background fluorescence of unlabeled SR vesicles in either normal or failing SR vesicles.

View larger version (45K): [in this window] [in a new window]   Figure 3. Specific incorporation of MCA into RyR moiety of SR. Electrophoresis was carried out on 4% SDS-polyacrylamide gel, and RyR was detected by staining with Coomassie blue (A, D) or by Western blot analysis (B, E) with a monoclonal antibody specific for canine cardiac RyR. Position of size markers (Bio-Rad) and resolving gel top (T) are as indicated on left. Difference in MCA fluorescence (arbitrary value; excitation 360 nm, emission 440 nm) between SAED-labeled and unlabeled samples is also indicated (C, F). MCA fluorescence is specifically localized to RyR band in both normal and failing SR vesicles.

View larger version (25K): [in this window] [in a new window]   Figure 4. A, Representative time courses of change in MCA fluorescence in absence or presence of FK506 during Ca2+ leak in SR vesicles isolated from normal and failing canine hearts. MCA fluorescence signal (arbitrary value) was recorded under same conditions as those used for Ca2+ leak assays, except that solution used was devoid of fluo 3. B, Effect of FK506 on conformational change in RyR during Ca2+ leak in SR vesicles isolated from normal (, n=6) and failing (•, n=6) canine hearts. Changes in fluorescence are expressed as (F-F0)/F0x100 (%), where F0 is before addition of FK506 and F after addition of FK506. Data represent mean±SD.

Changes in MCA fluorescence did not occur during an ionomycin-induced Ca²⁺ leak in either normal or failing SR vesicles (not shown), suggesting that the conformational change in RyR mediating the FK506-induced or spontaneous Ca²⁺ leak is not under the control of changes in intravesicular [Ca²⁺]. Furthermore, even when the extravesicular [Ca²⁺] was strictly buffered to 0.3 µmol/L (with 5 mmol/L EGTA-calcium buffer) during the FK506-induced Ca²⁺ leak, the change in MCA fluorescence was still observed (not shown), indicating that the FK506-induced conformational change in RyR is not under the control of changes in extravesicular [Ca²⁺] either.

FKBP12.6 Expression in Normal and Failing SR Vesicles
As shown in Figure 5, an immunoreactive band for FKBP12.6 was detected in both normal and failing SR vesicles. However, the expression level of FKBP12.6 was significantly lower (0.80±0.43) in failing SR vesicles than in normal SR vesicles (2.34±0.37).

View larger version (21K): [in this window] [in a new window]   Figure 5. A, Protein expression of FKBP12.6 in SR vesicles isolated from normal and failing canine hearts. Lane 1, 20 ng of FKBP12.6; lane 2, 100 µg of normal SR; lane 3, 100 µg of failing SR. Bands corresponding to FKBP12.6 are indicated by arrow. Position of size markers (Bio-Rad) is indicated on left. For details of experiments and antibodies used, see Methods. B, Statistical comparison of extent of FKBP12.6 expression between normal (n=5) and failing (n=5) SR vesicles. FKBP12.6 expression was lower in failing SR vesicles than in normal SR vesicles. Data represent mean±SD.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The major findings of this study are as follows. First, the stoichiometry of FKBP per RyR was significantly decreased in failing SR vesicles. Second, FK506, which binds to the FKBP12.6 associated with the RyR, caused a dose-dependent Ca²⁺ leak in normal SR vesicles that showed a close parallelism with the conformational change in RyR. Third, in failing SR vesicles, a prominent Ca²⁺ leak was observed even in the absence of FK506, and FK506 produced little or no further increase in Ca²⁺ leak and only a slight conformational change in RyR. Fourth, as we expected in view of the above results, the level of protein expression of FKBP12.6 was indeed significantly decreased in failing SR vesicles.

The most important new concept to emerge from these findings is that the abnormal Ca²⁺ leak observed in failing SR vesicles is due to a decreased stoichiometry of FKBP/RyR and the resultant conformational change in RyR, which leads to RyR instability. We interpret the time course of the FK506-induced change in MCA fluorescence as indicating that a conformational change in RyR occurred as a consequence of the dissociation of FKBP12.6 from RyR. Our results indicate that 50% of the FKBP12.6 molecules have already been lost from RyR in heart failure, whereas 4 FKBP12.6 molecules to be dissociated remain to be bound in the normal heart. Hence, treatment with FK506 would be expected to produce a much more conspicuous RyR conformational change in normal SR vesicles than in failing SR vesicles (in which a considerable portion of the RyR-bound FKBP12.6 has already been dissociated). Furthermore, the fact that the time course of the change in MCA fluorescence is much faster than that of the Ca²⁺ leak suggests that dissociation of the RyR-bound FKBP12.6 and the resultant RyR conformational change is a causative mechanism for the observed Ca²⁺ leak.

Our view, as deduced from the above findings, is schematically illustrated in Figure 6. When sufficiently high concentrations of FK506 (or rapamycin) are applied to cardiac myocytes, cooperation among the 4 RyR subunits is disrupted, thus destabilizing the channel and in turn inducing an abnormal Ca²⁺ leak. Presumably, equivalent phenomena are occurring in failing hearts even without the addition of FKBP-dissociating agents. This Ca²⁺ leak will decrease SR Ca²⁺ loading and elevate basal cytosolic Ca²⁺ levels during diastole, leading to contractile and relaxation dysfunction.

View larger version (25K): [in this window] [in a new window]   Figure 6. Altered interaction of FKBP12.6 with RyR in heart failure. Abnormal Ca2+ leak through the RyR is present in heart failure, presumably caused by partial loss of RyR-bound FKBP12.6 and resultant conformational change in RyR. This leak may cause Ca2+ overload and consequent diastolic dysfunction, as well as systolic dysfunction.

Before we can firmly advance this as an explanation, several questions remain to be resolved. Because FK506 binds to FKBP12 as well as to FKBP12.6, we need to examine the possibility that the B_max of [³H]dihydro-FK506 binding may indicate mixed binding of FK506, that is, to both FKBP12.6 and FKBP12. In this regard, we should note that in cardiac muscle, the type of FKBP bound to RyR is solely FKBP12.6 and that FKBP12 exists as a soluble form in the cytoplasm.⁹ Moreover, Lam et al⁸ showed that only FKBP12.6 was clearly detected (with no FKBP12) in a cardiac SR vesicle preparation that was similar to our preparation (see their Figure 5). In addition, in our study, the binding isotherm of [³H]dihydro-FK506 to cardiac SR vesicles is a simple hyperbola (yielding a straight line in a Scatchard analysis), a curve that is indicative of a single class of FK506 binding site. Taken together, the above evidence relating to [³H]dihydro-FK506 binding in cardiac SR vesicles indicates specific [³H]dihydro-FK506 binding to RyR-associated FKBP12.6.

The presumed stoichiometry of 4 mol FKBP12.6 per RyR tetramer relies on the assumption that the RyR is the predominant or only SR protein that binds FKBP12.6. In fact, Timerman et al⁹ have already confirmed that this is the case on the basis of the following findings. After the endogenous FKBP of cardiac SR was exchanged for GST-FKBP12.6 fusion protein, SR samples were solubilized with CHAPS and affinity-purified on a GST-Sepharose affinity column. The cardiac RyR (RyR-2) was the predominant protein that was tightly bound to the GST-FKBP12.6 in these SRs.

It might be questioned why the concentration of FK506 required to induce a Ca²⁺ leak and protein conformational change in RyR was considerably higher than that needed for FK506-FKBP12.6 binding. Ahern et al²² showed that the concentration of FK506 required for an increase in the open probability of RyR is 3 to 20 µmol/L, and Timerman et al¹⁷ demonstrated that the EC₅₀ for dissociation of FKBP from RyR was as high as 0.12 to 0.5 µmol/L. The concentration of FK506 required for its binding to FKBP12.6 may be higher under physiological conditions than in the solubilized conditions used for [³H]dihydro-FK506 binding assays.

Shou et al²³ used embryonic stem cells to generate mutant mice deficient in FKBP12 and demonstrated that although these FKBP12- (not 12.6)-deficient mice had normal skeletal muscle, they had severe dilated cardiomyopathy. Although FKBP12.6 seems to play an important role in the modulation of ryanodine receptor function in SR vesicles, more work is clearly needed before we can fully understand the roles of FKBP12 and 12.6 in cardiac function in the intact heart.

Finally, it remains to be elucidated why FKBP12.6 is partially lost in heart failure. Very recently, Marx et al²⁴ demonstrated that hyperphosphorylation of RyR mediated by protein kinase A causes dissociation of FKBP12.6 from RyR, resulting in defective channel function due to increased sensitivity to Ca²⁺-induced activation. Conceivably, this mechanism might be involved in the partial loss of FKBP12.6 seen in heart failure.

In conclusion, a prominent Ca²⁺ leak through the RyR was observed in a canine model of heart failure, and this is presumably caused by a partial loss of RyR-bound FKBP12.6. This abnormal Ca²⁺ leak could lead to systolic and diastolic dysfunction even in the absence of a change in SR Ca²⁺-ATPase activity. This new concept concerning the mechanism of cardiac dysfunction could inform the development of a new type of drug (ie, a Ca²⁺ channel stabilizer) for treatment of patients with heart failure.

	Acknowledgments

 
This work was supported by a grant-in-aid for scientific research from the Ministry of Education in Japan (grant C 11670684) and by a Health Sciences Research Grant for Comprehensive Research on Aging and Health from the Ministry of Health and Welfare, Japan. We thank Dr Noriaki Ikemoto (Department of Muscle Research, Boston Biomedical Research Institute, Boston, Mass) for a critical reading of the manuscript and helpful suggestions.

Received April 5, 2000; revision received May 29, 2000; accepted June 2, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245:C1–C14.[Abstract/Free Full Text]
   
2. Fabiato A. Time and calcium dependence of activation and inactivation of calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. J Gen Physiol. 1985;85:247–289.[Abstract/Free Full Text]
   
3. Ogawa Y. Role of ryanodine receptors. Crit Rev Biochem Mol Biol. 1994;29:229–274.[Medline] [Order article via Infotrieve]
   
4. Coronado R, Morrissette J, Sukhareva M, et al. Structure and function of ryanodine receptors. Am J Physiol. 1994;266:C1485–C1504.[Abstract/Free Full Text]
   
5. Jayaraman T, Brillantes AM, Timerman AP, et al. FK506-binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem. 1992;267:9474–9477.[Abstract/Free Full Text]
   
6. Marks AR. Intracellular calcium-release channels: regulators of cell life and death. Am J Physiol. 1997;272:597–605.
   
7. Brillantes A-M, Ondrias K, Andrew S, et al. Stabilization of calcium release channel (ryanodine receptor) function by FK 506-binding protein. Cell. 1994;77:513–523.[Medline] [Order article via Infotrieve]
   
8. Lam E, Martin MM, Timerman AP, et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J Biol Chem. 1995;270:26511–26522.[Abstract/Free Full Text]
   
9. Timerman AP, Onoue H, Xin HB, et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem. 1996;271:20385–20391.[Abstract/Free Full Text]
   
10. Sewell TJ, Lam E, Martin MM, et al. Inhibition of calcineurin by a novel FK-506-binding protein. J Biol Chem. 1994;269:21094–21102.[Abstract/Free Full Text]
    
11. Kaftan E, Marks AR, Ehrlich BE. Effects of rapamycin on ryanodine receptor/Ca²⁺-release channels from cardiac muscle. Circ Res. 1996;78:990–997.[Abstract/Free Full Text]
    
12. Yamamoto T, Yano M, Kohno M, et al. Abnormal Ca²⁺ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure. Cardiovasc Res. 1999;44:146–155.[Abstract/Free Full Text]
    
13. Noguchi N, Takasawa S, Nata K, et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca²⁺ from islet microsomes. J Biol Chem. 1997;272:3133–3136.[Abstract/Free Full Text]
    
14. Yano M, Yamamoto T, Kohno M, et al. Polylysine-induced rapid Ca²⁺ release from cardiac sarcoplasmic reticulum. J Cardiovasc Pharmacol. 1998;32:96–100.[Medline] [Order article via Infotrieve]
    
15. Kranias E, Schwarts A, Jungmann RA. Characterization of cyclic 3':5'-AMP-dependent protein kinase in sarcoplasmic reticulum and cytosol of canine myocardium. Biochim Biophys Acta. 1982;709:28–37.[Medline] [Order article via Infotrieve]
    
16. Siekierka J, Hung SHY, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755–757.[Medline] [Order article via Infotrieve]
    
17. Timerman AP, Ogunbumni E, Freund E, et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein: dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem. 1993;268:22992–22999.[Abstract/Free Full Text]
    
18. El-Hayek R, Yano M, Ikemoto N. A conformational change in the junctional foot protein is involved in the regulation of Ca²⁺ release from sarcoplasmic reticulum. J Biol Chem. 1995;270:15634–15638.[Abstract/Free Full Text]
    
19. Yano M, El-Hayek R, Ikemoto N. Role of calcium feed back in excitation-contraction coupling in isolated triads. J Biol Chem. 1995;270:19936–19942.[Abstract/Free Full Text]
    
20. Yano M, El-Hayek R, Ikemoto N. Conformational changes in the junctional foot protein/Ca²⁺ release channel mediated depolarization-induced Ca²⁺ release from sarcoplasmic reticulum. J Biol Chem. 1995;270:3017–3021.[Abstract/Free Full Text]
    
21. Meissner G, Henderson JS. Rapid calcium release from cardiac sarcoplasmic reticulum vesicles is dependent on Ca²⁺ and is modulated by Mg²⁺, adenine nucleotide, and calmodulin. J Biol Chem. 1987;262:3065–3073.[Abstract/Free Full Text]
    
22. Ahern GP, Junankar PR, Dulhunty AF. Single channel activity of the ryanodine receptor calcium release channel is modulated by FK-506. FEBS Lett. 1994;352:369–374.[Medline] [Order article via Infotrieve]
    
23. Shou W, Aghdasi B, Armstrong DL, et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP 12. Nature. 1998;391:489–492.[Medline] [Order article via Infotrieve]
    
24. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365–376.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				S. M. MacDonnell, G. Garcia-Rivas, J. A. Scherman, H. Kubo, X. Chen, H. Valdivia, and S. R. Houser Adrenergic Regulation of Cardiac Contractility Does Not Involve Phosphorylation of the Cardiac Ryanodine Receptor at Serine 2808 Circ. Res., April 25, 2008; 102(8): e65 - e72. [Abstract] [Full Text] [PDF]

				B. Gellen, M. Fernandez-Velasco, F. Briec, L. Vinet, K. LeQuang, P. Rouet-Benzineb, J.-P. Benitah, M. Pezet, G. Palais, N. Pellegrin, et al. Conditional FKBP12.6 Overexpression in Mouse Cardiac Myocytes Prevents Triggered Ventricular Tachycardia Through Specific Alterations in Excitation- Contraction Coupling Circulation, April 8, 2008; 117(14): 1778 - 1786. [Abstract] [Full Text] [PDF]

				T. Yamamoto, M. Yano, X. Xu, H. Uchinoumi, H. Tateishi, M. Mochizuki, T. Oda, S. Kobayashi, N. Ikemoto, and M. Matsuzaki Identification of Target Domains of the Cardiac Ryanodine Receptor to Correct Channel Disorder in Failing Hearts Circulation, February 12, 2008; 117(6): 762 - 772. [Abstract] [Full Text] [PDF]

				Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF]

				J. Xiao, X. Tian, P. P. Jones, J. Bolstad, H. Kong, R. Wang, L. Zhang, H. J. Duff, A. M. Gillis, S. Fleischer, et al. Removal of FKBP12.6 Does Not Alter the Conductance and Activation of the Cardiac Ryanodine Receptor or the Susceptibility to Stress-induced Ventricular Arrhythmias J. Biol. Chem., November 30, 2007; 282(48): 34828 - 34838. [Abstract] [Full Text] [PDF]

				T. Zhang, M. Kohlhaas, J. Backs, S. Mishra, W. Phillips, N. Dybkova, S. Chang, H. Ling, D. M. Bers, L. S. Maier, et al. CaMKII{delta} Isoforms Differentially Affect Calcium Handling but Similarly Regulate HDAC/MEF2 Transcriptional Responses J. Biol. Chem., November 30, 2007; 282(48): 35078 - 35087. [Abstract] [Full Text] [PDF]

				C. L.-H. HUANG, L. SUN, J. A. FRASER, A. A. GRACE, and M. ZAIDI Similarities and Contrasts in Ryanodine Receptor Localization and Function in Osteoclasts and Striated Muscle Cells Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 255 - 270. [Abstract] [Full Text] [PDF]

				S. Lehnart and A. R. Marks Regulation of Ryanodine Receptors in the Heart Circ. Res., October 12, 2007; 101(8): 746 - 749. [Full Text] [PDF]

				T. Seidler, G. Hasenfuss, and L. S. Maier Targeting Altered Calcium Physiology in the Heart: Translational Approaches to Excitation, Contraction, and Transcription Physiology, October 1, 2007; 22(5): 328 - 334. [Abstract] [Full Text] [PDF]

				R. P. Katra, T. Oya, G. S. Hoeker, and K. R. Laurita Ryanodine receptor dysfunction and triggered activity in the heart Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2144 - H2151. [Abstract] [Full Text] [PDF]

				M. Mochizuki, M. Yano, T. Oda, H. Tateishi, S. Kobayashi, T. Yamamoto, Y. Ikeda, T. Ohkusa, N. Ikemoto, and M. Matsuzaki Scavenging Free Radicals by Low-Dose Carvedilol Prevents Redox-Dependent Ca2+ Leak Via Stabilization of Ryanodine Receptor in Heart Failure J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1722 - 1732. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]

				H. E. D. J. ter Keurs and P. A. Boyden Calcium and Arrhythmogenesis Physiol Rev, April 1, 2007; 87(2): 457 - 506. [Abstract] [Full Text] [PDF]

				M. Yamada, Y. Ikeda, M. Yano, K. Yoshimura, S. Nishino, H. Aoyama, L. Wang, H. Aoki, and M. Matsuzaki Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy FASEB J, June 1, 2006; 20(8): 1197 - 1199. [Abstract] [Full Text] [PDF]

				S. E. Lehnart, C. Terrenoire, S. Reiken, X. H. T. Wehrens, L.-S. Song, E. J. Tillman, S. Mancarella, J. Coromilas, W. J. Lederer, R. S. Kass, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias PNAS, May 16, 2006; 103(20): 7906 - 7910. [Abstract] [Full Text] [PDF]

				X. H. T. Wehrens, S. E. Lehnart, S. Reiken, J. A. Vest, A. Wronska, and A. R. Marks Inaugural Article: Ryanodine receptor/calcium release channel PKA phosphorylation: A critical mediator of heart failure progression PNAS, January 17, 2006; 103(3): 511 - 518. [Abstract] [Full Text] [PDF]

				M. R. Sharma, L. H. Jeyakumar, S. Fleischer, and T. Wagenknecht Three-Dimensional Visualization of FKBP12.6 Binding to an Open Conformation of Cardiac Ryanodine Receptor Biophys. J., January 1, 2006; 90(1): 164 - 172. [Abstract] [Full Text] [PDF]

				M. Yano, S. Okuda, T. Oda, T. Tokuhisa, H. Tateishi, M. Mochizuki, T. Noma, M. Doi, S. Kobayashi, T. Yamamoto, et al. Correction of Defective Interdomain Interaction Within Ryanodine Receptor by Antioxidant Is a New Therapeutic Strategy Against Heart Failure Circulation, December 6, 2005; 112(23): 3633 - 3643. [Abstract] [Full Text] [PDF]

				X. H. T. Wehrens, S. E. Lehnart, S. Reiken, R. van der Nagel, R. Morales, J. Sun, Z. Cheng, S.-X. Deng, L. J. de Windt, D. W. Landry, et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure PNAS, July 5, 2005; 102(27): 9607 - 9612. [Abstract] [Full Text] [PDF]

				S. E. Lehnart, X. H.T. Wehrens, and A. R. Marks Defective Ryanodine Receptor Interdomain Interactions May Contribute to Intracellular Ca2+ Leak: A Novel Therapeutic Target in Heart Failure Circulation, June 28, 2005; 111(25): 3342 - 3346. [Full Text] [PDF]

				T. Oda, M. Yano, T. Yamamoto, T. Tokuhisa, S. Okuda, M. Doi, T. Ohkusa, Y. Ikeda, S. Kobayashi, N. Ikemoto, et al. Defective Regulation of Interdomain Interactions Within the Ryanodine Receptor Plays a Key Role in the Pathogenesis of Heart Failure Circulation, June 28, 2005; 111(25): 3400 - 3410. [Abstract] [Full Text] [PDF]

				X. H.T. WEHRENS, S. E. LEHNART, and A. R. MARKS Ryanodine Receptor-Targeted Anti-Arrhythmic Therapy Ann. N.Y. Acad. Sci., June 1, 2005; 1047(1): 366 - 375. [Abstract] [Full Text] [PDF]

				J. A. Vest, X. H.T. Wehrens, S. R. Reiken, S. E. Lehnart, D. Dobrev, P. Chandra, P. Danilo, U. Ravens, M. R. Rosen, and A. R. Marks Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation Circulation, April 26, 2005; 111(16): 2025 - 2032. [Abstract] [Full Text] [PDF]

				A. Baartscheer, C. A. Schumacher, M. M.G.J. van Borren, C. N.W. Belterman, R. Coronel, T. Opthof, and J. W.T. Fiolet Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure Cardiovasc Res, January 1, 2005; 65(1): 83 - 92. [Abstract] [Full Text] [PDF]